The impressive beneficial effect of ustekinumab therapy, the lack of adverse events, the rapid response after failure of the three anti-TNF drugs, and the improvement in quality of life all warrant the need for new studies to examine the full potential of this new drug in the treatment of EP.
References1 Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12 ⁄ 23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-74. 2 Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12 ⁄ 23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-84. 3 Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12 ⁄ 23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-40. Erratum in: Lancet 2009; 373: 1340. 4 Pink AE, Fonia A, Allen MH et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-a therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010 [Epub ahead of print].